The neurobehavioural effects of kava

Australian and New Zealand Journal of Psychiatry

Volumn 36, Issue 5, 2002, Pages 657-662

  Cairney, Sheree ^a   Maruff, Paul ^a   Clough, Alan R ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Anaesthesia; Anxiolytic; Choreoathetosis; Kava; Psychoactive

Indexed keywords

ION CHANNEL; KAVA EXTRACT; PLACEBO;

ADULT; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANXIETY NEUROSIS; ARTICLE; AUSTRALIA; CHANNEL GATING; COGNITION; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG USE; DYSTONIA; EMOTIONAL STRESS; ETHNIC GROUP; HERBAL MEDICINE; HUMAN; MALE; MEDLINE; MUSCLE RELAXATION; NERVE CELL STIMULATION; NONHUMAN; PSYCHOPHARMACOLOGY; PSYCHOSIS; RISK FACTOR; TRANQUILIZING ACTIVITY;

ADULT; ATHETOSIS; CHOREA; CLINICAL TRIALS; COGNITION; DOUBLE-BLIND METHOD; HUMANS; KAVA; MALE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0036799167     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2002.01027.x     Document Type: Article

References (63)

1. Duffield AM, Jamieson DD. Chemistry and pharmacology of kava. In: Prescott J, McCall G, eds. Kava: use and abuse in Australia and the South Pacific. Sydney: National Drug and Alcohol Research Centre (Monograph no. 5). 1988: 1-12.
2. Pfeiffer CC, Murphree HB, Goldstein L. Effect of kava in normal subjects and patients. In: Efron DH, Holmstedt B, Kline NS, eds. Ethnopharmacological search for psychoactive drugs. Washington DC: Public Health Service Publication No 1645, 1967: 155-161.
3. Shulgin AT. The narcotic pepper - the chemistry and pharmacology of piper methysticum and related species. Bulletin of Narcotics 1973; 25:59-74.
4. Pittler MH, Ernst E. Efficiacy of kava extract for treating anxiety. systematic review and meta-analysis. Journal of Clinical Psychopharmacology 2000; 20:84-89.
5. Lebot V, Merlin M, Lindstrom L. Kava, the Pacific elixir: the definitive guide to its ethnobotany, history and chemistry, 2nd edn. Rochester, Vermont: Healing Arts Press, 1997.
6. Cawte J. Parameters of kava used as a challenge to alcohol. Australian and New Zealand Journal of Psychiatry 1986; 20:70-76.
7. Singh YN. Kava: an overview. Journal of Ethnopharmacology 1992; 37:13-45.
8. Naisilisili S. Social and behavioural issues related to kava consumption: a study of kava drinking in Fiji. Pacific Islands Nutrition 1999; 41:11-12.
9. McDonald D, Jowitt A. Kava in the Pacific Islands. A contemporary drug of abuse? Drug and Alcohol Review 2000; 19:217-227.
10. d'Abbs P. A review of kava control measures in the Northern Territory. Darwin: Menzies School of Health Research, 1993.
11. Douglas W. The effects of heavy usage of kava on physical health [letter]. The Medical Journal of Australia 1988; 149:341-342.
12. Mathews JD, Riley MD, Fejo L et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an Aboriginal community. The Medical Journal of Australia 1988; 148:548-555.
13. Markowitz JS. Herbal medicines assuming larger role in psychiatric care. Drug Topics 1998; 142:50-53.
14. Wong AHC, Smith M, Boon HS. Herbal remedies in psychiatric practice. Archives in General Psychiatry 1998; 55:1033-1044.
15. Zinberg NE. Drug, Set and Setting: the Basis for Controlled Intoxicant Use. New Haven: Yale University Press, 1984.
16. Schultes RE, Hofmann A. Plants of the gods: their sacred, healing and hallucinogenic powers. Rochester: Healing Arts Press, 1992.
17. Brunton R. Kava and the daily dissolution of society on Tanna, New Hebrides. Mankind 1979; 12:93-103.
18. Turner J. The water of life: kava ritual and the logic of sacrifice. Ethnology 1986; 25:203-214.
19. Turner J. Substance, symbol and practice: the power of kava in Fijian society. Canberra Anthropology 1995; 18:97-118.
20. Gregory RJ, Cawte JE. The principles of alien poisons. contrasting psychopharmacology of kava in Oceania and Australia. In: Prescott J, McCall G, eds. Kava: use and abuse in Australia and the South Pacific Sydney: University of New South Wales (Monograph no. 5). 11-11- 1988, 29-39.
21. Sahlins M. How natives think about Captain Cook, for example. Chicago: University of Chicago Press, 1995.
22. Dunlop I. We believe in it: we know it's true [videocassette]. Lindfield, NSW: Film Australia, 1996.
23. Williams N. The Yolngu and their land: a system of land tenure and the fight for its recognition. Canberra: Australian Institute of Aboriginal Studies, 1986.
24. Reid J. Sorcerers and Healing Spirits. Canberra: Australian National University, 1983.
25. Cawte J. Healers of Arnhem Land. Sydney: University of New South Wales, 1996.
26. Moyles W. Aboriginal community use of kava as an alcohol substitute. Balmain: Aboriginal Training and Cultural Institute, 1982.
27. Ford CS. Ethnographical aspects of kava. In: Efron DH, Holmstedt B, Kline NS, eds. Ethnopharmacological search for psychoactive drugs. Washington DC: Public Health Service Publication No 1645, 1967: 162-173.
28. Clough AR, Burns CB, Mununggurr N. Kava in Arnhem Land: a review of consumption and its social correlates. Drug and Alcohol Review 2000; 19:319-328.
29. Rotblatt MD. Medicine cabinets: cranberry, feverfew, horse chestnut, and kava. Western Journal of Medicine 1999; 171:195-198.
30. Schelosky L, Raffauf C, Jendroska, K, Poewe W. Kava and dopamine antagonism. Journal of Neurology, Neurosurgery and Psychiatry 1995; 58:639-640.
31. Brunton R. A harmless substance? Anthropological aspects of kava in the South Pacific. In: Prescott J, McCall G, eds. Kava: use and abuse in Australia and the South Pacific Sydney: National Drug and Alcohol Research Centre (Monograph no. 5). 11-11- 1988, 13-25.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington DC: American Psychiatric Association, 1994.
33. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug and Alcohol Review 1997; 16:147-155.
34. Almeida JA, Grimsley E. Coma from the health food store: interaction between kava and alprazolam. Annals of Internal Medicine 1996; 125:940-941.
35. Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of kava intoxication. The Medical Journal of Australia 1997; 167:172-173.
36. Klohs MW. Chemistry of kava. In: Efron DH, Hohnstedt B, Kline NS, eds. Ethnopharmacological Search for Psychoactive Drugs Washington DC: Public Health Service Publication No 1645, 1967:126-132.
37. Jamieson DD, Duffield PH, Cheng D, Duffield AM. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch International Pharmacodyn 1989; 301:66-80.
38. Meyer HJ. Pharmacology of Kava. In: Efron DH, Holmstedt B, Kline NS, eds. Ethnopharmacological Search for Psychoactive Drugs Washington DC: Public Health Service Publication No 1645, 1967:133-140.
39. Keledjian J, Duffield PH, Jamieson DD, Lidgard RO, Duffield AM. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. Journal of Pharmaceutical Sciences 1988; 77:1003-1006.
40. Davies LP, Drew CA, Duffield P, Johnston GAR, Jamieson DD. Kava pyrones and resin: studies of GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacology & Toxicology 1992; 71:120-126.
41. Walden J, Von Wegerer J, Winter U, Berger M. Actions of kavain and dihydromethysticin on ipsapirone-induced field potential changes in the hippocampus. Human Psychopharmacology 1997; 12:265-270.
42. Gleitz J, Friese J, Beile A, Ameri A, Peters T. Anticonvulsive action of (+/-) -kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. European Journal of Pharmacology 1996; 315:89-97.
43. Singh YN. Effects of kava on neuromuscular transmission and muscle contractility. Journal of Ethnopharmacology 1983; 7:267-276.
44. Gleitz J, Beile A, Peters T. (+/-) -kavain inhibits veratridine-activated voltage-dependent Na+-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology 1995; 34:1133-1138.
45. Magura. EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Kava extract ingredients, (+) -methysticin (±) -kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience 1997; 81:345-351.
46. Langosch JM, Normann C, Schirrmacher K, Berger M, Walden J. The influence of (±) -kavain on population spikes and long-term potentiation in guinea pig hippocampal slices. Comparative Biochemistry and Physiology Part A 1998; 120:545-549.
47. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Medica 1997; 63:548-549.
48. Walden J, Von Wegerer J, Winter U, Berger M, Grunze H. Effects of kawain and dihydromethysticin on field potential charges in the hippocampus. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1997; 21:697-706.
49. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998; 31:187-192.
50. Schirrmacher K, Busselberg D, Langosch JM, Walden J, Winter U, Bingmann D. Effects of (+/-) -kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats. European Neuropsychopharmacology 1999; 9:171-176.
51. Gleitz J, Beile A, Peters T. (+/-) -kavain inhibits veratridine- and KCl-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology 1996; 35:179-186.
52. Duffield PH, Jamieson DD, Duffield AM. [Effect of aqueous and lipid-soluble extracts of kava on the conditioned avoidance response in rats.] Archives Internationales de Pharmacodynamie et de Therapie 1989; 301:81-90. (In French.)
53. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1998; 22:1105-1120.
54. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994; 116:469-474.
55. Buckley JP, Furgiuele AR, O'Hara MJ. Pharmacology of kava. In: Efron DH, Holmstedt B, Kline NS, eds. Ethnopharmacological search for psychoactive drugs Washington DC: Public Health Service Publication No 1645, 1967:141-151.
56. Holm E, Staedt U, Heep J et al. [The action profile of D, 1-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals]. Arzneimittel-Forschung 1991; 41:673-683. [German].
57. Boonen G, Ferger B, Kuschinsky K, Haberlein H. In Vivo effects of the kavapyrones (+) -dihydromethysticin (+/-) -kavain on dopamine, 3, 4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Medica 1998; 64:507-510.
58. Bliss TVP, Collingridge GL. A synaptic model of memory long-term potentiation in the hippocampus. Nature 1993; 361:31-39.
59. Russell PN, Bakker D, Singh N. The effects of kava on alerting and speed of access of information from long-term memory. Bulletin of the Psychonomic Society 1987; 25:236-237.
60. Prescott J, Jamieson D, Emdur N, Duffield P. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug and Alcohol Review 1993; 12:49-58.
61. Monte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27:46-53.
62. Heinze HJ, Münthe TF, Steitz J, Matzke M. Pharmacological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 1994; 27:224-230.
63. Saletu B, Grünberger J, Linzmayer L, Anderer P. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain - a kava plant derivative. Human Psychopharmacology 1989; 4:169-190.